Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15367119 | 1.00 | METAP2 (0.65) | METAP2 | |
| SCHEMBL12469451 | 1.00 | METAP2 (0.65) | METAP2 | |
| SCHEMBL15320046 | 0.90 | METAP2 (0.55) | METAP2 | |
| SCHEMBL17328518 | 0.85 | METAP2 (0.56) | METAP2 | |
| SCHEMBL17328679 | 0.85 | METAP2 (0.50) | METAP2 | |
| SCHEMBL17328532 | 0.85 | METAP2 (0.56) | METAP2 | |
| SCHEMBL17328524 | 0.85 | METAP2 (0.50) | METAP2 | |
| SCHEMBL17328527 | 0.85 | METAP2 (0.50) | METAP2 | |
| SCHEMBL17328521 | 0.85 | METAP2 (0.56) | METAP2 | |
| SCHEMBL15367309 | 0.85 | METAP2 (0.63) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627631-B1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-12-16 | — | — | EP | claimed |
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| CN-104245675-B | Cyclic amides as MetAP-2 inhibitors | 默克专利股份公司 | 2017-10-13 | — | — | CN | disclosed |
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| CN-103153951-B | Pyrrolidones as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | CN | disclosed |
| EP-2627631-B1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2834221-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | Merck Patent GmbH (DE) | 2015-02-11 | — | — | EP | disclosed |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| CN-104245675-A | Cyclic amides as MetAP-2 inhibitors | MERCK PATENT GMBH | 2014-12-24 | — | — | CN | disclosed |
| US-8895535-B2 | Pyrrolidinones as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| WO-2013149704-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013149704-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
| EP-2627631-A1 | PYRROLIDINONES AS METAP2 INHIBITORS | Merck Patent GmbH (DE) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012048775-A1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | METAP2, METAP1, LNPEP | METAP2 1/4885 |
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | METAP1, METAP2, DNPEP | METAP2 2/4885 |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | METAP2, METAP1, ENPEP | METAP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.